INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

	June 30, 2024								December 31, 2023
(in millions)	Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(7,399)	$	—	$	3,321	$	10,720	$	(7,050)	$	—	$	3,670
Intangible asset – axicabtagene ciloleucel	7,110		(2,517)		—		4,593		7,110		(2,314)		—		4,796
Intangible asset – Trodelvy	11,730		(2,543)		—		9,187		11,730		(2,002)		—		9,728
Intangible asset – Hepcludex	845		(286)		—		559		845		(243)		—		602
Other	1,414		(883)		1		533		1,414		(827)		1		588
Total finite-lived assets	31,819		(13,628)		1		18,192		31,819		(12,436)		1		19,384
Indefinite-lived assets – IPR&D(1)	4,640		—		—		4,640		7,070		—		—		7,070
Total intangible assets	$	36,459	$	(13,628)	$	1	$	22,832	$	38,889	$	(12,436)	$	1	$	26,454

_______________________________

(1)    The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairment” below for 2024 activity.

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

	June 30, 2024								December 31, 2023
(in millions)	Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross  Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(7,399)	$	—	$	3,321	$	10,720	$	(7,050)	$	—	$	3,670
Intangible asset – axicabtagene ciloleucel	7,110		(2,517)		—		4,593		7,110		(2,314)		—		4,796
Intangible asset – Trodelvy	11,730		(2,543)		—		9,187		11,730		(2,002)		—		9,728
Intangible asset – Hepcludex	845		(286)		—		559		845		(243)		—		602
Other	1,414		(883)		1		533		1,414		(827)		1		588
Total finite-lived assets	31,819		(13,628)		1		18,192		31,819		(12,436)		1		19,384
Indefinite-lived assets – IPR&D(1)	4,640		—		—		4,640		7,070		—		—		7,070
Total intangible assets	$	36,459	$	(13,628)	$	1	$	22,832	$	38,889	$	(12,436)	$	1	$	26,454

_______________________________

(1)    The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairment” below for 2024 activity.